Yama F Mujadidi

BCA Computer Application , MSc in Information Technology and Software Engineering

Clinical Trials IT and Development Lead

Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.

Recent publications

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
Journal article

Liu X. et al, (2022), J Infect
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.
Journal article

Ogbe A. et al, (2022), JCI Insight
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article

Stuart ASV. et al, (2021), Lancet
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Journal article

Munro APS. et al, (2021), Lancet
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article

Clemens SAC. et al, (2021), Nature Communications, 12
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Journal article

Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568
Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Journal article

Theiss-Nyland K. et al, (2021), Clin Infect Dis
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Journal article

Clemens SAC. et al, (2021), Nat Commun, 12
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
Journal article

Swanson PA. et al, (2021), Sci Transl Med
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article

Feng S. et al, (2021), Nat Med
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Journal article

Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article

Liu X. et al, (2021), Lancet, 398, 856 - 869
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Journal article

Qadri F. et al, (2021), Lancet, 398, 675 - 684
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Journal article

Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Journal article

Swanson PA. et al, (2021), medRxiv
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article

Liu X. et al, (2021), SSRN Electronic Journal
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Journal article

Flaxman A. et al, (2021), SSRN Electronic Journal
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article

Barrett JR. et al, (2021), Nat Med, 27
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article

Ewer KJ. et al, (2021), Nat Med, 27
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article

Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Journal article

Madhi SA. et al, (2021), N Engl J Med, 384, 1885 - 1898
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection
Frater J. et al, (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article

Voysey M. et al, (2021), Lancet, 397, 881 - 891
Successful incorporation of a genetic risk prediction research platform into routine newborn screening
Journal article

Bendor-Samuel OM. et al, (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Journal article

Emary KRW. et al, (2021), SSRN Electronic Journal
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Journal article

Voysey M. et al, (2021), The Lancet
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article

Ewer KJ. et al, (2021), Nat Med, 27, 270 - 278

More publications